Details

Autor(en) / Beteiligte

• Le, Gia Han
• Wong, Sabrina
• Badulescu, Sebastian
• Au, Hezekiah
• Di Vincenzo, Joshua D.
• Gill, Hartej
• Phan, Lee
• Rhee, Taeho Greg
• Ho, Roger
• Teopiz, Kayla M.
• Kwan, Angela T.H.
• Rosenblat, Joshua D.
• Mansur, Rodrigo B.
• McIntyre, Roger S.

Titel

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review

Ist Teil von

• Journal of affective disorders, 2024-06, Vol.355, p.342-354

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Electrophysiologic measures provide an opportunity to inform mechanistic models and possibly biomarker prediction of response. Serotonergic psychedelics (SPs) (i.e., psilocybin, lysergic acid diethylamide (LSD)) and ketamine represent new investigational and established treatments in mood disorders respectively. There is a need to better characterize the mechanism of action of these agents. We conducted a systematic review investigating the spectral signatures of psilocybin, LSD, and ketamine in persons with major depressive disorder (MDD), treatment-resistant depression (TRD), and healthy controls. Ketamine and SPs are associated with increased theta power in persons with depression. Ketamine and SPs are also associated with decreased spectral power in the alpha, beta and delta bands in healthy controls and persons with depression. When administered with SPs, theta power was increased in persons with MDD when administered with SPs. Ketamine is associated with increased gamma band power in both healthy controls and persons with MDD. The studies included in our review were heterogeneous in their patient population, exposure, dosing of treatment and devices used to evaluate EEG and MEG signatures. Our results were extracted entirely from persons who were either healthy volunteers or persons with MDD or TRD. Extant literature evaluating EEG and MEG spectral signatures indicate that ketamine and SPs have reproducible effects in keeping with disease models of network connectivity. Future research vistas should evaluate whether observed spectral signatures can guide further discovery of therapeutics within the psychedelic and dissociative classes of agents, and its prediction capability in persons treated for depression. •Serotonergic psychedelics (SPs) decreased gamma power in healthy controls.•Ketamine & SPs increased theta power in persons with depression.•Ketamine & SPs decreased alpha, beta, and delta power in healthy and MDD persons.•Ketamine increased gamma power in both healthy and MDD persons.